Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
The addition of the Phase III candidate to its portfolio positions Merck as a leader in the race to launch a low-cost version of a major rheumatoid arthritis drug.
The addition of the Phase III candidate to its portfolio positions Merck as a leader in the race to launch a low-cost version of a major rheumatoid arthritis drug.